Akrevia Therapeutics
2015
FOUNDED
PRIVATE
STATUS
Series B
LATEST DEAL TYPE
$60.3M
LATEST DEAL AMOUNT
4
INVESTORS
Description
Developer of the next generation of cancer immunotherapies intended to discover and develop better, safer immunotherapeutics. The company's proprietary platform helps to produce cancer immunotherapies that are specifically activated in the local environment of the cancer and achieves precise targeting of therapeutic, enabling healthcare professionals to discover immune stimulating molecules and antibodies.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- LabCentral 610
- 610 Main Street
- Cambridge, MA 02139
- United States
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Akrevia Therapeutics’s full profile, request a free trial.
Akrevia Therapeutics Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC (Series B) | 12-Dec-2019 | $60.3M | 000.00 | Completed | Product Development | |
| 2. Early Stage VC (Series A1) | 27-Sep-2018 | 0000 | 000.00 | Completed | Product Development | |
| 1. Early Stage VC (Series A) | 12-Oct-2016 | $7.5M | $7.5M | Completed | Startup |
Akrevia Therapeutics Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| NS Investments | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Atlas Venture | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Eight Roads | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| F-Prime Capital Partners | Venture Capital | Minority | 000 0000 | 000000 0 |
Akrevia Therapeutics Executive Team (7)
2 Former Executives
You’re viewing 5 of 7 executives. Get the full list »Akrevia Therapeutics Board Members (10)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Benjamin Auspitz | Akrevia Therapeutics | Board Member | 000 0000 | |
| David Grayzel MD | Atlas Venture | Board Member | 000 0000 | |
| Jessica Alston Ph.D | F-Prime Capital Partners | Board Observer | 000 0000 | |
| Michael Gladstone | Atlas Venture | Board Member | 000 0000 | |
| Nessan Bermingham Ph.D | Atlas Venture | Chairman | 000 0000 |
3 Former Board Members
You’re viewing 5 of 10 board members. Get the full list »